Palisade Bio (PALI) Expected to Post Earnings on Monday

Palisade Bio (NASDAQ:PALI) is anticipated to post its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Palisade Bio to post earnings of ($0.05) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, analysts expect Palisade Bio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Palisade Bio Stock Performance

Shares of PALI opened at $1.90 on Monday. Palisade Bio has a one year low of $0.53 and a one year high of $2.85. The stock has a 50-day moving average price of $1.93 and a 200 day moving average price of $1.90. The company has a market capitalization of $328.93 million, a P/E ratio of -1.88 and a beta of 1.52.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Oppenheimer initiated coverage on shares of Palisade Bio in a research note on Thursday, July 23rd. They set an “outperform” rating and a $8.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Finally, Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $9.00.

Insider Activity

In other Palisade Bio news, CEO John David Finley sold 146,798 shares of Palisade Bio stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total value of $303,871.86. Following the completion of the transaction, the chief executive officer owned 217,555 shares of the company’s stock, valued at $450,338.85. The trade was a 40.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera bought 25,000 shares of the stock in a transaction on Thursday, July 9th. The shares were acquired at an average price of $1.96 per share, with a total value of $49,000.00. Following the purchase, the director owned 461,904 shares of the company’s stock, valued at $905,331.84. The trade was a 5.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 125,000 shares of company stock worth $250,100. 0.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC acquired a new position in shares of Palisade Bio in the 4th quarter valued at about $24,822,000. RA Capital Management L.P. bought a new position in Palisade Bio in the fourth quarter worth about $16,742,000. Franklin Resources Inc. acquired a new position in Palisade Bio in the fourth quarter valued at approximately $11,968,000. Adage Capital Partners GP L.L.C. acquired a new position in Palisade Bio in the fourth quarter valued at approximately $10,575,000. Finally, Squadron Capital Management LLC bought a new position in shares of Palisade Bio during the fourth quarter valued at approximately $10,575,000. 11.79% of the stock is owned by institutional investors and hedge funds.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.